These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 31353964

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B.
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ.
    Orphanet J Rare Dis; 2018 Dec 17; 13(1):225. PubMed ID: 30558645
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance.
    Ishii T, Hirano Y, Matsumoto N, Takata A, Sekijima Y, Ueda M, Ando Y.
    Clin Ther; 2020 Sep 17; 42(9):1728-1737.e6. PubMed ID: 32800381
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
    Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB.
    Amyloid; 2017 Sep 17; 24(3):194-204. PubMed ID: 28758793
    [Abstract] [Full Text] [Related]

  • 10. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 17; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 11. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May 17; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 12. Tafamidis: a review of its use in familial amyloid polyneuropathy.
    Scott LJ.
    Drugs; 2014 Aug 17; 74(12):1371-8. PubMed ID: 25022953
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Labeyrie C, Merkel M, Sethi S, Popadic L, Yang H, Sweetser MT, Lin H, Adams D.
    Eur J Neurol; 2024 Sep 17; 31(9):e16384. PubMed ID: 38988097
    [Abstract] [Full Text] [Related]

  • 14. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA, Salvo EM, Tran D, Amass L, Stewart M, Cameron C.
    Curr Med Res Opin; 2020 May 17; 36(5):799-808. PubMed ID: 32011182
    [Abstract] [Full Text] [Related]

  • 15. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
    Sanso MAR, Rodriguez AR, Vicente LM, Sevilla T, Garro CB, Martín JF, Vicente AA, de la Prida MM, Dávila LG, Vázquez LG, Valle FM, Pons CC, Bau AF, Barroso EC, López IL, González-Moreno J.
    Med Clin (Barc); 2024 May 17; 162(9):e27-e32. PubMed ID: 38556397
    [Abstract] [Full Text] [Related]

  • 16. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec 17; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Circ Heart Fail; 2022 Jan 17; 15(1):e008193. PubMed ID: 34923848
    [Abstract] [Full Text] [Related]

  • 18. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    N Engl J Med; 2018 Sep 13; 379(11):1007-1016. PubMed ID: 30145929
    [Abstract] [Full Text] [Related]

  • 19. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M.
    Expert Opin Pharmacother; 2019 Mar 13; 20(4):473-481. PubMed ID: 30489166
    [Abstract] [Full Text] [Related]

  • 20. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.
    Circ Heart Fail; 2015 May 13; 8(3):519-26. PubMed ID: 25872787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.